19 October 2012, EMA/CHMP/675745/2012, Press release http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/10/news_detail_001638.jsp&mid=WC0b01ac058004d5c1
Leggi
AIFA, 14 novembre 2012 http://www.agenziafarmaco.gov.it/sites/default/files/determinazione__allegato_a.pdf
Leggi
European Medicines Agency 07/12/2012 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002322/human_med_001546.jsp&mid=WC0b01ac058001d124
Leggi
AIFA - Agenzia Italiana del Farmaco 14 dicembre 2012 http://www.agenziafarmaco.gov.it/it/content/domande-e-risposte-su-solumarv-isomarv-medium-e-combimarv-insulina-umana-14122012
Leggi
AIFA - Agenzia del farmaco 7 gennaio 2013 http://www.agenziafarmaco.gov.it/it/content/nota-informativa-importante-su-tredaptive-trevaclyn-pelzont-07012013
Leggi
FDA NEWS RELEASE - For Immediate Release: Jan. 25, 2013 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336942.htm?source=govdelivery
Leggi
FDA Drug Safety Communication: 14/3/2013 http://www.fda.gov/Drugs/DrugSafety/ucm343187.htm
Leggi
Agenzia Italiana del Farmaco (AIFA) - 26 marzo 2013 http://www.agenziafarmaco.gov.it/it/content/comunicato-stampa-ema-sulle-terapie-basate-sul-glp-1-incretino-mimetici-nel-trattamento-del-
Leggi
First in a new class of diabetes drugs FDA NEWS RELEASE: 29/3/2013 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm
Leggi
22 March 2013 - EMA/98571/2013 http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Cilostazol-containing_medicines/human_referral_000338.jsp&mid=WC0b01ac05805c516f
Leggi
